Modulation of radiation-induced oral mucositis by pentoxifylline: Preclinical studies

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Sylvia Gruber - , Medizinische Universität Wien (Autor:in)
  • Margret Schmidt - , Deutsches Krebsforschungszentrum (DKFZ), Klinik und Poliklinik für Strahlentherapie und Radioonkologie, OncoRay - National Centre for Radiation Research in Oncology, Deutsches Konsortium für Translationale Krebsforschung (DKTK) - Dresden (Autor:in)
  • Eva Bozsaky - , Medizinische Universität Wien (Autor:in)
  • Kathrin Wolfram - , Klinik und Poliklinik für Strahlentherapie und Radioonkologie, OncoRay - National Centre for Radiation Research in Oncology (Autor:in)
  • Julia Haagen - , Klinik und Poliklinik für Strahlentherapie und Radioonkologie, OncoRay - National Centre for Radiation Research in Oncology (Autor:in)
  • Bettina Habelt - , Klinik und Poliklinik für Strahlentherapie und Radioonkologie, OncoRay ZIC - Nationales Zentrum für Strahlenforschung in der Onkologie (Partner/Träger: UKD, HZDR) (Autor:in)
  • Martin Puttrich - , Klinik und Poliklinik für Strahlentherapie und Radioonkologie, OncoRay - National Centre for Radiation Research in Oncology (Autor:in)
  • Wolfgang Dörr - , Medizinische Universität Wien, Klinik und Poliklinik für Strahlentherapie und Radioonkologie, OncoRay - National Centre for Radiation Research in Oncology (Autor:in)

Abstract

Background and purpose: Oral mucositis is a frequent early side effect of radio(chemo)therapy of head-and-neck malignancies. The epithelial radiation response is accompanied by inflammatory reactions; their interaction with epithelial processes remains unclear. The aim of the present study was to investigate the effect of pentoxifylline (PTX) on the oral mucosal radiation response in the mouse tongue model. Materials and methods: Irradiation comprised fractionation (5 fractions of 3 Gy/week) over 1 (days 0–4) or 2 weeks (days 0–4, 7–11), followed by graded local top-up doses (day 7/14), in order to generate complete dose–effect curves. PTX (15 mg/kg subcutaneously) was applied once daily over varying time intervals. Ulceration of mouse tongue epithelium, corresponding to confluent mucositis, was analyzed as the clinically relevant endpoint. Results: With fractionated irradiation over 1 week, PTX administration significantly reduced the incidence of mucosal reactions when initiated before (day − 5) the onset of fractionation; a trend was observed for start of PTX treatment on day 0. Similarly, PTX treatment combined with 2 weeks of fractionation had a significant effect on ulcer incidence in all but one experiment. This clearly illustrates the potential of PTX to ameliorate oral mucositis during daily fractionated irradiation. Conclusion: PTX resulted in a significant reduction of oral mucositis during fractionated irradiation, which may be attributed to stimulation of mucosal repopulation processes. The biological basis of this effect, however, needs to be clarified in further, detailed mechanistic studies.

Titel in Übersetzung
Modulation der strahleninduzierten oralen Mukositis durch Pentoxifyllin
Präklinische Studien

Details

OriginalspracheEnglisch
Seiten (von - bis)242-247
Seitenumfang6
FachzeitschriftStrahlentherapie und Onkologie
Jahrgang191
Ausgabenummer3
PublikationsstatusVeröffentlicht - 24 Feb. 2015
Peer-Review-StatusJa

Externe IDs

PubMed 25351168

Schlagworte

Schlagwörter

  • Animal model, Fractionated irradiation, Inflammation, Oral mucositis, Pentoxifylline